Renal Insufficiency in Non-Diabetic Subjects: Relationship of MTHFR C677t Gene Polymorphism and Left Ventricular Hypertrophy

Figures & data

Table 1. Characteristic of study population and differences between MTHFR polymorphism and control group.

	Total (n.138)	MTHFR Polymorphism (n. 100)	Wild MTHFR AA (n. 38)	p
Age, y	50.15 ± 15.44	49.47 ± 16.62	51.95 ± 11.81	0.402
BMI, Kg/m^2	28.00 ± 6.17	28.12 ± 6.44	>27.70 ± 5.47	0.726
hsCRP, mg/dL	2.77 ± 4.28	2.78 ± 4.09	2.74 ± 4.79	0.959
Blood glucose, mg/dL	93.74 ± 24.07	95.60 ± 27.31	88.84 ± 10.79	0.141
GFR	69.43 ± 29.12	73.68 ± 27.89	58.27 ± 29.69	0.005
Triglycerides, mg/dL	106.80 ± 60.56	103.46 ± 51.82	115.61 ± 79.27	0.294
Total cholesterol, mg/dL	203.73 ± 44.61	206.86 ± 44.93	195.49 ± 43.25	0.182
HDL cholesterol, mg/dL	57.32 ± 17.88	56.53 ± 16.09	59.39 ± 22.02	0.402
LDL cholesterol, mg/dL	125.20 ± 41.49	129.85 ± 42.25	112.97 ± 37.24	0.032
HOMA	2.72 ± 2.77	2.95 ± 3.14	2.12 ± 1.20	0.117
PTH, pg/mL	73.82 ± 100.78	72.90 ± 107.51	76.24 ± 81.69	0.863
Vit. B12, mcg/dL	488.17 ± 280.23	471.77 ± 237.69	531.34 ± 370.07	0.266
Folic acid, ng/mL	9.91 ± 19.33	10.13 ± 22.55	9.33 ± 4.72	0.830
AMDS	34.64 ± 3.04	34.58 ± 3.22	34.78 ± 2.53	0.739
NT-proBNP, pg/mL	65.77 ± 41.55	65.21 ± 44.23	67.24 ± 33.99	0.799
Homocysteine, µmol/L	20.75 ± 4.89	21.27 ± 5.02	19.37 ± 4.27	0.040
Albumin, g/dL	4.92 ± 3.81	5.03 ± 4.47	4.64 ± 0.29	0.596
RRI	0.61 ± 0.06	0.60 ± 0.07	0.62 ± 0.06	0.093
EF %	67.25 ± 8.07	67.13 ± 8.02	67.54 ± 8.30	0.803
E/A	1.19 ± 0.29	1.20 ± 0.28	1.14 ± 0.31	0.303
LVMM/m^2	97.50 ± 35.09	98.54 ± 30.36	94.76 ± 45.64	0.574
Women, n	75	56	19	0.659

Notes: BMI, body mass index; hsCRP, high-sensitivity C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RRI, renal resistive index; EF, ejection fraction; LVMM, left ventricular mass myocardial. Bold fonts indicate significant results. *Pearson chi-square.

Table 2. Multiple linear regression predictive model for LVMM/m² and GFR.

LVMM/m^2
Predictors	R	R^2	F	Significance	β	p
	0.424	0.180	3.120	0.002
HOMA					0.028	0.749
MTHFR polymorphism					−0.099	0.243
RRI					0.070	0.490
GFR					−0.338	0.001
iPTH, pg/mL					0.031	0.731
Homocysteine, µmol/L					0.129	0.127
Vit. B12, mcg/dL					0.051	0.556
Folic acid, ng/mL					−0.141	0.110
AMDS					−0.009	0.923
GFR
Predictors	R	R^2	F	Significance	β	p
	0.672	0.452	11.728	<0.0001
HOMA					0.008	0.908
MTHFR polymorphism					0.154	0.026
RRI					−0.438	<0.0001
LVMM/m^2					−0.226	<0.001
iPTH, pg/mL					−0.193	0.007
Homocysteine, µmol/L					−0.050	0.475
Vit. B12, mcg/dL					−0.022	0.761
Folic acid, ng/mL					0.066	0.362
AMDS					−0.091	0.203

Notes: BMI, body mass index; RRI, renal resistive index; LVMM, left ventricular mass myocardial; AMDS, adherence Mediterranean diet score. Weighted by age least squares multiple regression. Bold fonts indicate significant predictive results.

Figure 1. Higher concentration of parathyroid hormone (iPTH) (OR, 5.377; 95% CI, 1.202–24.051), greater levels of high-sensitivity C-reactive protein (hsCRP) (OR, 3.156; 95% CI, 0.885–11.255), older age (OR, 4.543; 95% CI, 1.012–20.397), and left ventricular hypertrophy (LVH) (OR, 1.942; 95% CI, 0.819–4.293) are associated significantly with renal insufficiency; MTHFR 677C>T polymorphism is associated significantly with lower odds of renal insufficiency (OR, 0.443; 95% CI, 0.141–1.387).